Skip to main content

Turning down the volume on fibromyalgia pain


Ginevra Liptan MD


Fibromyalgia is a common condition of widespread pain reflecting central nervous system sensitization. Fibromyalgia pain is notoriously resistant to standard treatments, in part because they do not address the key contribution of the glial cells, the support and immune cells that surround neurons. Central sensitization is a complex process resulting in abnormal glial cell activation and inflammation.

Low-dose naltrexone (LDN) calms activated glial cells and lowers the volume of pain transmitted to the brain. Stanford University researchers found in two separate studies that LDN substantially reduced fibromyalgia pain. Clinical experience supports these research findings, and the presentation will briefly review 4 years of data from use of LDN in a fibromyalgia specialty practice and methods to avoid interactions with opiate-based pain medications.

Session Learning Objectives:

1) Describe the pathophysiology of fibromyalgia pain

2) Review research data supporting use of LDN in fibromyalgia

3) Identify ways to avoid interactions between opiate-based pain medications and LDN

4) Understand additive benefits of CBD (cannabidiol) and LDN